Following a quiet stretch, the legal back-and-forth over migraine meds from Teva and Eli Lilly has resurfaced, with Teva ...
The Federal Circuit reversed a ruling that had wiped out Teva Pharmaceuticals International GmbH’s $177 million Ajovy patent ...
The Food and Drug Administration has approved Teva’s Ajovy for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or ...
A U.S. appeals court on Thursday revived a patent lawsuit that Teva Pharmaceutical brought against Eli Lilly over the ...
If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in ...
Treatment with fremanezumab led to a significantly greater reduction in monthly migraine days and monthly headache days. The Food and Drug Administration (FDA) has approved Ajovy ® (fremanezumab-vfrm) ...
PARSIPPANY, N.J. and TEL AVIV, Israel, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the ...
LAS VEGAS -- Fremanezumab (Ajovy) received FDA approval in 2018 for the prevention of episodic and chronic migraine prevention. But the trials supporting approval of the agent, which functions by ...
CINCINNATI (WKRC) - A medication previously available only for adults is now on the market for children to help reduce migraines. Recent research focused on children aged six to 17 and examined a ...
We recently compiled a list of the 10 Overlooked Healthcare Stocks to Invest in. Teva Pharmaceutical Industries Limited is one of them. Teva Pharmaceutical Industries Limited (NYSE:TEVA) tops our list ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results